Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis - PubMed
14 hours ago
- #Lebrikizumab
- #remission
- #atopic dermatitis
- Lebrikizumab monotherapy showed efficacy in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
- The study evaluated the relationship between lebrikizumab serum levels and sustained deep response after treatment cessation in Week 16-responder patients.
- Analysis pooled data from two phase 3 trials, ADvocate1 and ADvocate2, focusing on patients who maintained stable EASI 90 response post-induction up to Week 52.
- 28% of responders maintained stable EASI 90 response during withdrawal, with no or minimal fluctuations, without rescue medication.
- Mean serum lebrikizumab levels decreased by 92% from Week 16 to Week 32 and over 99% by Week 52.
- Lebrikizumab demonstrated off-therapy maintenance of response in a subset of AD patients for at least 38 weeks post-discontinuation.